ATX — Amplia Therapeutics Share News
0.000.00%
- AU$40.53m
- AU$13.02m
Brief: Ampila Therapeutics Announces Granting Of Key Patent In Europe And Japan
Australia's Amplia Therapeutics jumps most in 3 yrs on upbeat cancer drug trial results
Australia's Amplia Therapeutics up on funding to advance cancer trial
Brief: Amplia Therapeutics Says Completed A$4.27 Million Fully Underwritten Entitlement Offer
Brief: Amplia Therapeutics Says Fully Underwritten 2 For 5 Entitlement Offer
Australia's Amplia Therapeutics falls on discounted capital raising
Brief: Amplia Therapeutics Seeks Trading Halt
Australia's Amplia Therapeutics rises on FDA nod for cancer drug trial
Brief: Amplia Therapeutics Announces FDA Clearance Of IND For Pancreatic Cancer Trial In US
Brief: Amplia Therapeutics Seeks Trading Halt
Brief: Amplia Therapeutics Says Approval From Korean Regulator
Brief: Amplia Therapeutics Says Tim Luscombe Will Replace Hamish George As CFO
Australia's Amplia Therapeutics climbs on receiving grant
Brief: Amplia Therapeutics Says Grant Funding Received To Support Research Collaboration With Csiro
Brief: Amplia Therapeutics Says Dose Escalation Approved In Accent Clinical Trial Of Amp945
Brief: Amplia Therapeutics Appoints Christopher Burns As CEO & Managing Director
Brief: Amplia Therapeutics Announces CEO Resignation
Australia's Amplia climbs as lung disorder drug shows efficacy
Australia's Amplia Therapeutics rises on approval for cancer treatment study